Analysts Set NeoGenomics, Inc. (NASDAQ:NEO) PT at $19.89

Shares of NeoGenomics, Inc. (NASDAQ:NEO) have been assigned an average rating of “Moderate Buy” from the ten research firms that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $19.89.

Several research analysts recently weighed in on the stock. Benchmark restated a “buy” rating and issued a $18.00 price objective on shares of NeoGenomics in a research report on Tuesday, September 24th. Needham & Company LLC restated a “buy” rating and issued a $19.00 price objective on shares of NeoGenomics in a research report on Wednesday, September 25th. Finally, Stephens restated an “overweight” rating and issued a $19.00 price objective on shares of NeoGenomics in a research report on Tuesday, July 30th.

NeoGenomics Trading Down 0.1 %

Shares of NEO opened at $13.53 on Friday. The business’s 50-day moving average price is $15.64 and its 200-day moving average price is $14.84. NeoGenomics has a twelve month low of $11.97 and a twelve month high of $21.22. The stock has a market cap of $1.73 billion, a PE ratio of -20.50 and a beta of 1.19. The company has a quick ratio of 1.93, a current ratio of 2.01 and a debt-to-equity ratio of 0.37.

NeoGenomics (NASDAQ:NEO) last posted its quarterly earnings data on Monday, July 29th. The medical research company reported $0.03 earnings per share for the quarter. The company had revenue of $164.50 million for the quarter, compared to analysts’ expectations of $161.82 million. NeoGenomics had a negative net margin of 12.50% and a negative return on equity of 2.72%. NeoGenomics’s revenue for the quarter was up 12.0% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.09) earnings per share. On average, equities analysts forecast that NeoGenomics will post -0.21 EPS for the current fiscal year.

Institutional Trading of NeoGenomics

A number of institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its stake in shares of NeoGenomics by 0.3% during the first quarter. Vanguard Group Inc. now owns 14,211,019 shares of the medical research company’s stock valued at $223,397,000 after purchasing an additional 41,354 shares during the period. First Light Asset Management LLC raised its holdings in shares of NeoGenomics by 14.5% during the second quarter. First Light Asset Management LLC now owns 3,782,561 shares of the medical research company’s stock valued at $52,464,000 after acquiring an additional 480,396 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of NeoGenomics by 7.0% during the second quarter. Dimensional Fund Advisors LP now owns 3,324,624 shares of the medical research company’s stock valued at $46,108,000 after acquiring an additional 217,687 shares in the last quarter. American Century Companies Inc. raised its holdings in shares of NeoGenomics by 5.4% during the second quarter. American Century Companies Inc. now owns 3,261,756 shares of the medical research company’s stock valued at $45,241,000 after acquiring an additional 167,145 shares in the last quarter. Finally, Jennison Associates LLC raised its holdings in shares of NeoGenomics by 77.8% during the first quarter. Jennison Associates LLC now owns 1,051,627 shares of the medical research company’s stock valued at $16,532,000 after acquiring an additional 460,071 shares in the last quarter. Hedge funds and other institutional investors own 98.50% of the company’s stock.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.